Tag: NHL
TRPH-222 Shows High Response and a Favorable Safety Profile in Non-Hodgkin’s...
Updated results from its Phase 1 multi-center, open-label, monotherapy study of TRPH-222 (formerly called CAT-02-106) in heavily pre-treated patients with relapsed and/or refractory (R/R)...
ASH 2020: Positive Interim Phase I Study Results of TRPH-222 in...
TRPH-222 (CD22-4AP), an antibody-drug conjugate (ADC) being developed by Triphase, demonstrated early signs of efficacy with favorable tolerability at higher dose levels in patients...
First Patients Dosed with Combination of Loncastuximab Tesirine + Ibrutinib in...
Diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) are two distinct subtypes of non-Hodgkin lymphoma (NHL). These hematological malignancies are associated with...
TRPH-222, a Novel Anti-CD22 ADC, has Significant Anti-Tumor Activity in NHL
A preclinical abstract describing TRPH-222, also known as CAT-02-106, an anti-CD22 antibody-drug conjugate or ADC being developed by Triphase Accelerator for the treatment of...
Updates from the 14th International Conference on Malignant Lymphoma (ICML)
Since the inaugurational meeting in 1981, the International Conference on Malignant Lymphoma (ICML), traditionally takes place in Lugano, Switzerland, has become one of the...
Debiopharm Acquires Phase II IMGN529 from ImmunoGen
Debiopharm International, a Swiss biopharmaceutical company, has confirmed that it has acquired ImmunoGen's IMGN529, also known as Debio 1562 or naratuximab emtansine, a clinical-stage anti-CD37 antibody-drug...
Alcanza Trial Demonstrates Highly Statistically Significant Improvement in Rate of Objective...
Results of the phase III Alcanza trial evaluating brentuximab vedotin (Adcetris®; Takeda Pharmaceutical and Seattle Genetics) in patients with cutaneous T-cell lymphoma (CTCL) shows...
Novel ADC Technology Demonstrated Strong Preclinical Antitumor Activity in B-cell Malignancies...
Lymphomas, a group of cancers that originate in the lymphatic system, include both Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Non-Hodgkin lymphoma, which is...
Denintuzumab Mafodotin: Testing Novel Regimens for Frontline and Relapsed DLBCL
Highlighted clinical data with denintuzumab mafodotin (SGN-CD19A; 19A; Seattle Genetics) in B-cell malignancies, including diffuse large B-cell lymphoma, also known as DLBCL, and B-lineage...
First of Two Planned Trials Combining Brentuximab Vedotin and Nivolumab Start...
Seattle Genetics, a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer, has initiated a phase 1/2...
